A presentation from Kent’s Local HealthWatch Development Group covering the perspectives of the NHS, Centre for Public Scrutiny and local authority. This is a useful planning tool for local healthwatch groups.
Developed by The King's Fund in partnership with the RCGP, the Nuffield Trust and Hempsons Solicitors, this toolkit provides advice and support to practitioners and managers in primary care who are thinking about, or have already embarked upon, developing a federation to provide and develop services collaboratively.
Developed by The King's Fund in partnership with the RCGP, the Nuffield Trust and Hempsons Solicitors, this toolkit provides advice and support to practitioners and managers in primary care who are thinking about, or have already embarked upon, developing a federation to provide and develop services collaboratively.
hsns09:The Scottish telecare development programme:the evaluation - Sophie BealeIriss
Sophie Beale,York Health Economics Consortium,University of York.
http://php.york.ac.uk/inst/yhec/?q=contact/keycontacts
Connected Practice Symposium,Human Services in the Network Society,Changes, Challenges & Opportunities. The Institute for Advanced Studies, Glasgow 14-15 September 2009.
http://connectedpractice.iriss.org.uk/
hsns09:Ethical considerations around telecare-Andrew EcclesIriss
Andrew Eccles, Lecturer, Glasgow School of Social Work.
http://www.strath.ac.uk/gssw/staff/gsswstaff/ecclesandrewmr/
Connected Practice Symposium,Human Services in the Network Society,Changes, Challenges & Opportunities. The Institute for Advanced Studies, Glasgow 14-15 September 2009.
http://connectedpractice.iriss.org.uk/
THE CHILD’S JOURNEY
The Munro Review Interim Report 1st February 2011
‘A breakthrough in child protection?’
A seminar presented by Richard Walne at Cass Business School
ZeroDivide set out to identify the key barriers to increased philanthropic investment in nonprofits' use of technology, recognizing there is tremendous interest and need by organizations based in underserved communities.
This project builds on the findings of previous studies, while contributing unique aspects to the conversation.
Download the full report http://bit.ly/gbM7AU
Feature presentation - The economic case for action
Professor Martin Knapp, Director, Health &
Personal Social Services Research Unit, London School of Economics & Kings College London
hsns09:The Scottish telecare development programme:the evaluation - Sophie BealeIriss
Sophie Beale,York Health Economics Consortium,University of York.
http://php.york.ac.uk/inst/yhec/?q=contact/keycontacts
Connected Practice Symposium,Human Services in the Network Society,Changes, Challenges & Opportunities. The Institute for Advanced Studies, Glasgow 14-15 September 2009.
http://connectedpractice.iriss.org.uk/
hsns09:Ethical considerations around telecare-Andrew EcclesIriss
Andrew Eccles, Lecturer, Glasgow School of Social Work.
http://www.strath.ac.uk/gssw/staff/gsswstaff/ecclesandrewmr/
Connected Practice Symposium,Human Services in the Network Society,Changes, Challenges & Opportunities. The Institute for Advanced Studies, Glasgow 14-15 September 2009.
http://connectedpractice.iriss.org.uk/
THE CHILD’S JOURNEY
The Munro Review Interim Report 1st February 2011
‘A breakthrough in child protection?’
A seminar presented by Richard Walne at Cass Business School
ZeroDivide set out to identify the key barriers to increased philanthropic investment in nonprofits' use of technology, recognizing there is tremendous interest and need by organizations based in underserved communities.
This project builds on the findings of previous studies, while contributing unique aspects to the conversation.
Download the full report http://bit.ly/gbM7AU
Feature presentation - The economic case for action
Professor Martin Knapp, Director, Health &
Personal Social Services Research Unit, London School of Economics & Kings College London
Maxine Powers, National Improvement Advisor at Department of Health, addresses Why QIPP and why now?, Programme design, National Work stream plans for safety and the role and contribution of AHPs. COT Annual Conference 2010 (22-25 June 2010)
The Home-Based Memory Rehabilitation Programme (for persons with mild Alzheimer’s disease and other dementias)
Mary McGrath, Advanced Clinical Specialist Occupational Therapist
Memory Clinic, Belfast City Hospital
27 September 2012 - National End of Life Care Programme
We set out to gather the current, available information on costing end of life care to inform a more robust steer for the potential costs and savings that the EoLC national programme can utilise as a framework for the QIPP activities for 2012/13 and beyond.
We examined the available evidence to address three key questions:
What learning has there been, especially in the last two years?
What does this tell us?
What is there that can be extrapolated into the national arena?
In all, 57 documents were analysed, to seek the answers to 8 questions relating to end of life care costs in acute hospital settings and in community settings and to consider the potential cost savings of shifting the place of care.
From this we concluded:
There is a wealth of information to draw on and there is merit and learning in bringing the end of life care costing information into this one 'snap shot' report
The variability of the work being reported leads to significant limitations of the findings that can be made in this report
There are no robust, agreed costs of end of life care, but there is a range of costing information to draw
on to inform the range of costs for end of life care in acute and community settings
We do not know from the documents analysed if the cost of an admission ending in death or the cost
of an inpatient day for the episode that ends in death is greater than, equal to or less than the current
'price'; the complexities of 'cost', 'price' and tariff are explored further in the report
There are potential savings that could be released by shifting care from the acute to the community
setting if such is the patient's wish and if the commensurate disinvestment in acute care systems can be achieved
The document analysis shows that there is concern about the ability of current systems to realise the
changes needed to release the funds for reinvestment and/or savings
There is much work still to do to develop robust cost information to support the continued development
of high quality, cost effective end of life care
The work of the Palliative Care Funding Pilots (PCFPs) to develop the per-patient funding tariff through highlighting the actual costs of palliative and end of life care will greatly clarify the answers to some of the questions posed here.
Publication by the National End of Life Programme which became part of NHS Improving Quality in May 2013
From a talk to the Workshop on Integrated Strategy on Healthy Living and Chronic Diseases, Ottawa, February 2011.
Knowledge exchange is more than just a compilation or warehousing of data or information. To generate new knowledge we must infuse data with new meaning. We do this not in an additive way from single actions and data-bits, but by creating a story about the overall pattern embedded in events and data and then using that story to understand more clearly the events and data that gave rise to it.
Jim Warren
National Institute for Health Innovation (NIHI)
The University of Auckland
The presentation was accompanied by this video:
http://www.youtube.com/watch?v=jbvmGqmIxXY
Realising the Value Stakeholder Event -Workshop: How does the system support Nesta
Workshop D - How does the system support communities/individuals and how could it do it better?
The levers and drivers that national bodies put in place and how these are used locally have a significant impact on working in partnership with communities and patients. These levers and drivers include regulation, targets, outcomes measures, financial flows, annual contracting cycles, clinical standards, workforce training and revalidation etc.
This workshop will draw upon your experience and evidence to address two questions:
How these levers and drivers get in the way of working in partnership with patients and communities?
What is the best blend of approaches to support commissioners and providers locally to harness the energy of patients and communities
The dos and don'ts of user and employee engagement, with case studies from business and a focus on engagement in health and care - including measurement and stakeholders engagement planning.
Cheryl and Rachael will talk about how they are working to modernise workforce practicesand attract, recruit, retain a more inclusive workforce that delivers world class healthcare
Using Data, Transforming Practice: Evaluating Mental Health Transformation in...MHTP Webmastere
Using Data, Transforming Practice: Evaluating Mental Health Transformation in Washington State</strong><br />
This presentation, made in February 2008 to the 18th Annual Conference on State Mental Health Agency Services
Research, details the approach of the Mental Health Transformation Project in using data to evaluate transformation
Community Engagement of Sexual & Gender Minority PopulationsCHICommunications
This session, tailored for intermediate learners, offers a deep dive into patient and community engagement in health research, specifically focusing on its pivotal role in driving policy change. Learners will emerge equipped with:
🟠 A comprehensive understanding of the benefits of patient and community engagement in health research.
🟠 The ability to articulate the principles of authentic patient and community engagement.
🟠 A clear definition of intersectionality and practical insights into incorporating its principles into their patient and community engagement strategies.
🟠 An appreciation for the pivotal role of advocacy and the development of public- and stakeholder-facing materials in research programs aimed at influencing health policy.
Creating digital tools for mental health and employment support: the discover...Department of Health
This report maps out the needs of potential users of an online mental health and work assessment and support service, suggests key user groups and presents a set of design principles for any a potential future service.
Creating digital tools for mental wellbeing and employment support: pre-alpha...Department of Health
This slide-deck reports on the second phase user research and testing. It presents refined design briefs that can be used to inform future alpha stages and design of a future service. These are themed according to the three core user groups identified in the first phase:
(i) finding work
(ii) in and out of work
(iii) managing work.
Further information on:
- user testing details
- mock-ups of potential digital tools for people finding work
- mock-ups of potential digital tools for people moving in and out of work
- mock-ups of potential digital tools for people managing work
Global Dementia Legacy Event: Canada & France: Dr Etienne Hirsch & Dr Yves Jo...Department of Health
Session Five: The next goal – towards Canada, France, Japan and the United States.
Canada & France: Dr Etienne Hirsch, Director, Institute for Neurosciences, Cognitive sciences, Neurology and Psychiatry at INSERM and the French alliance for life and health science Aviesan & Dr Yves Joanette CIHR, Scientific Director, Canadian Institutes of Health Research (CIHR), Institute of Aging & World Dementia Council Member
Session Four: Exploring the financial mechanisms that can be harnessed to increase investment in
dementia.
Professor Andrew Lo, MIT Sloan Professor of Finance
Session Four: Exploring the financial mechanisms that can be harnessed to increase investment in
dementia.
Mr. George Vradenburg, Convenor, The Global CEO Initiative on Alzheimer's and Chairman of USAgainstAlzheimer’s & World Dementia Council Member
Marc Wortman, Executive Director, Alzheimer’s Disease International (ADI) Department of Health
Session Three: To explore ways in which we can increase investment in innovation. Part 2 presents a case study of innovation across the globe and the need to continue global collaboration
Marc Wortman, Executive Director, Alzheimer’s Disease International (ADI)
Session Three: To explore ways in which we can increase investment in innovation. Part 2 presents a case study of innovation across the globe and the need to continue global collaboration
DY Suharya, Executive Director of Alzheimer's Indonesia
Session Three: To explore ways in which we can increase investment in innovation. Part 2 presents a case study of innovation across the globe and the need to continue global collaboration
Dr. Maria C. Carrillo, Vice President, Alzheimer’s Association US
Session 3: To explore ways in which we can increase investment in innovation. In part 1 panellists will highlight ways in which they are seeking to tackle barriers and find solutions, including through big data, patient involvement in clinical trials and social investment.
Mr. Stephen Johnston, Co-Founder, Aging2.0 & Partner, Generator Ventures
Session 3: To explore ways in which we can increase investment in innovation. In part 1 panellists will highlight ways in which they are seeking to tackle barriers and find solutions, including through big data, patient involvement in clinical trials and social investment.
Mr. Tom Wright CBE, Group CEO, Age UK
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia
Dr Neil Buckholtz , Director of Neuroscience, the National Institute on Aging (NIA), National Institutes of Health (NIH)
Global Dementia Legacy Event: Ms Inez Jabalpurwala, President and CEO, Brain ...Department of Health
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia
Ms Inez Jabalpurwala, President and CEO, Brain Canada Foundation
Global Dementia Legacy Event: Raj Long, Senior Regulatory OfficerDepartment of Health
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia.
Raj Long, Senior Regulatory Officer – Integrated Development, Global Health at the Bill & Melinda Gates Foundation & World Dementia Council Member
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia.
Dr. Luc Truyen, MD, PhD, VP Neuroscience External Affairs and Chair, Johnson&Johnson, Global Fight against !lzheimer’s Disease
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia.
Elisabetta Vaudano DVM PhD, Coordinator Scientific Pillar, Principal Scientific Manager, Innovative Medicines Initiative
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia.
John Ryan, Acting Director of the European Commission Public Health Directorate
Session Two: Barriers to investment in research to find a disease modifying therapy or cure for dementia.
Professor Lefkos Middleton, Professor of Neurology, Neuroepidemiology and Ageing Research at School of Public Health, Imperial College London
Dr Shekhar Saxena, Director of the Department of Mental Health and Substance Abuse at World Health Organization (WHO) & Technical Advisor to the World Dementia Council
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874